Vectus Biosystems Limited (ASX:VBS), an Australian clinical-stage biotechnology company focused on fibrotic disease therapies, has appointed Dr Tara Speranza as Chief Executive Officer and Chief Technology Officer, effective 7 May 2026. The company simultaneously completed a $791,000 placement to accelerate Phase Ib clinical trial work for its lead compound VB0004, while completing the out-licensing of its VB4-P5 renal compound to Canadian biotech firm XORTX Therapeutics, securing an equity stake in the process. These developments position Vectus for an expanded research and development phase as it advances toward regulatory milestones in the United States.

Key Points

  • Vectus Biosystems Limited (ASX:VBS) is an Australian clinical-stage biotechnology company developing novel therapies for fibrotic diseases, with VB0004 as its lead compound targeting idiopathic pulmonary fibrosis (IPF)
  • Dr Tara Speranza appointed CEO and CTO on 7 May 2026, bringing over two decades of experience in scientific research, drug development, biotechnology commercialisation, and capital markets
  • The company completed a $791,000 placement of 7,910,000 ordinary shares at $0.10 per share in May 2026 to fund VB0004 Phase Ib clinical trials and other drug programmes
  • VB4-P5 renal compound out-licensed to XORTX Therapeutics in April 2026 in exchange for 154,544 XORTX common shares (9.9% of XORTX) and 692,150 pre-funded warrants, retaining future development exposure
  • Cardinal Health Regulatory Services (CHRS) engaged as US Regulatory Agent to lead FDA-facing activities for VB0004, including Orphan Drug Designation and IND application for IPF
  • Cash-on-hand as at 30 June 2026 was $718,000; quarterly commercialisation, patent, staff and Phase I costs totalled $74,000
  • Investors should monitor progress toward FDA pre-IND communications, Orphan Drug Designation approval, and advancement of the VB0004 Phase Ib clinical programme

Dr Tara Speranza's Appointment Strengthens Leadership Capabilities for Clinical Progression

Vectus Biosystems has appointed Dr Tara Speranza as Chief Executive Officer and Chief Technology Officer, effective 7 May 2026. Dr Speranza brings more than two decades of professional experience spanning scientific research, translational drug development, biotechnology commercialisation, strategic advisory work, and capital markets activities. Prior to her formal appointment, she had provided consulting services to the company since August 2025, ensuring continuity of understanding regarding Vectus' scientific platform, its lead compound VB0004, and its broader portfolio of drug candidates.

Her academic background includes senior research positions at the University of Sydney and the University of Geneva, where her work focused on identifying novel molecular targets and translating scientific discoveries into potential therapeutic products. Notably, during her academic career, Dr Speranza led a commercial partnership with global pharmaceutical company Servier that contributed to the development and commercialisation of an anti-osteoporotic therapy. Following her transition from academia, she held investment, advisory, and capital markets roles supporting healthcare and biotechnology companies with valuation analysis, capital raising strategies, strategic positioning, and transaction execution. Her experience includes assessing and progressing investments and partnerships across early and late-stage healthcare assets, including licensing and other strategic transaction processes.

The appointment is expected to strengthen Vectus' organisational capabilities as the company progresses into its next development phase. Dr Speranza's combined scientific, commercial, and capital markets expertise is positioned to support the advancement of VB0004 into additional clinical studies while assisting the company's engagement with potential strategic, licensing, and commercial partners. Subsequent to her appointment, Dr Speranza hosted an investor webinar to provide updates on Vectus' strategic direction, corporate priorities, and development plans.

$791,000 Capital Placement Funds Acceleration of VB0004 Phase Ib Clinical Trials

In May 2026, Vectus Biosystems completed a placement of 7,910,000 new fully paid ordinary shares at $0.10 per share, raising $791,000 in gross proceeds. The placement was supported by a number of qualifying sophisticated investors and did not include any related parties of the company. This capital raise represents a strategic injection of funding to accelerate the company's clinical development activities during a critical phase of its therapeutic pipeline advancement.

The net proceeds from the placement are being deployed to accelerate the Phase Ib clinical trial for VB0004, which targets the prevention and reversal of fibrosis in the lungs, heart, and kidneys. Beyond the lead programme, the company is also using placement proceeds to advance its other emerging lead compounds and to support working capital requirements. This allocation of capital reflects Vectus' prioritisation of clinical development while maintaining operational efficiency. The placement was completed at a time when the company had recently appointed its new leadership team and was preparing for expanded engagement with United States regulatory authorities.

VB4-P5 Out-Licensing Transaction Provides Strategic Equity Exposure to XORTX Therapeutics

In April 2026, Vectus Biosystems finalised the out-licensing of its VB4-P5 renal small molecule compound to XORTX Therapeutics Inc., a Canadian biotechnology company listed on the Nasdaq exchange and previously on the TSX Venture Exchange. The transaction closed on 14 April 2026 following satisfaction of all closing conditions. As consideration for the transaction, XORTX issued Vectus 154,544 common shares, representing approximately 9.9% of XORTX's issued share capital, together with 692,150 pre-funded warrants that may be exercised into shares without any additional material payment by Vectus. Certain portions of these securities are subject to voluntary lock-up periods ranging from 45 to 180 days following completion of the transaction.

Under the transaction terms, XORTX acquired the patents, intellectual property, and data specifically relating to VB4-P5 and its potential application in renal fibrosis and kidney disease. Importantly, Vectus retained a licence to the relevant patents and intellectual property for potential applications outside those therapeutic fields, preserving flexibility for future development opportunities in alternative disease areas. Through its holding in XORTX, Vectus retains meaningful exposure to the future development and commercialisation of VB4-P5, as well as to XORTX's broader development portfolio, without being required to provide further funding for those programmes. This transaction structure allows Vectus to participate in the value creation of VB4-P5 development while focusing its internal resources on VB0004 advancement.

Cardinal Health Regulatory Services Engaged as US Regulatory Agent for FDA Submissions

Subsequent to the end of the June 2026 quarter, Vectus Biosystems announced the engagement of Cardinal Health Regulatory Services (CHRS) as its United States Regulatory Agent. CHRS will act as the primary point of contact for all Food and Drug Administration (FDA)-facing regulatory activities for VB0004, the company's lead compound, and potentially for other pipeline assets as they advance through development. This engagement represents a strategic step toward US regulatory engagement and represents an important infrastructure investment for clinical development progression.

Under the engagement arrangement, CHRS will facilitate and prepare all FDA-facing communications, interactions, and submissions on behalf of Vectus. The scope of CHRS responsibilities includes preparation of an Orphan Drug Designation Request for VB0004, pre-Investigational New Drug (pre-IND) communications with the FDA, and the formal IND application for VB0004 in idiopathic pulmonary fibrosis (IPF). Cardinal Health Regulatory Services is described as a leading US regulatory affairs consultancy with deep expertise in FDA submissions and drug development strategies. The engagement of experienced regulatory counsel aligns with Vectus' strategic priority of advancing VB0004 toward clinical studies in the United States market and demonstrates preparation for engagement with the FDA on matters related to IPF indication development.

VB0004 Mechanism and Clinical Development Status in Fibrotic Disease Treatment

VB0004 is Vectus Biosystems' lead compound and is described as a first-in-class antifibrotic candidate that has demonstrated the ability to reverse established fibrosis in preclinical models. The compound has successfully completed Phase Ia clinical studies, during which it established a favourable safety and pharmacokinetic profile in human subjects. The advancement to Phase Ib clinical trial work represents the next stage of human clinical evaluation and will provide opportunities for further characterisation of the compound's safety, tolerability, and preliminary efficacy in target patient populations.

The initial therapeutic focus for VB0004 is idiopathic pulmonary fibrosis (IPF), a progressive and often fatal lung disease characterised by significant unmet medical need. IPF represents a substantial clinical opportunity given the limited treatment options currently available and the progressive nature of the condition. However, VB0004's mechanism—targeting the prevention and reversal of fibrosis—has potential application across multiple organ systems. The company's development strategy encompasses potential use of VB0004 in fibrosis affecting the lungs, heart, and kidneys, reflecting the broad applicability of the antifibrotic mechanism. This multi-organ indication strategy could provide multiple pathways for value creation and commercial development as the compound progresses through the clinical development pipeline.

Financial Position and Cost Management During Development Phase

As at 30 June 2026, Vectus Biosystems reported cash-on-hand of $718,000. During the June 2026 quarter, payments expended by the company were in connection with commercialisation of VB0004, intellectual property renewals, and corporate overheads. The company reported that payments for commercialisation, patents, staff costs, and Phase I activities during the quarter totalled $74,000. This cost structure reflects the company's focus on targeted development spending while managing operational efficiency during the clinical-stage development phase.

Payments to related parties during the June 2026 quarter included CEO salary of $28,000 and fees of $11,000 for corporate services (including cost reimbursement in line with budget) paid to Regional Corporate Services Pty Ltd, of which Non-Executive Director Maurie Stang is a director. The company has significantly reduced its operating costs and is focused on potential licensing opportunities and a variety of collaborations. The capital raise completed in May 2026 is expected to extend the company's cash runway and support acceleration of VB0004 Phase Ib clinical trial work. The strategic focus on cost management while maintaining development momentum reflects the company's approach to capital efficiency during the clinical advancement stage.

Strategic Positioning for Licensing and Partnership Opportunities

Vectus Biosystems has positioned itself to pursue potential licensing opportunities and collaborative arrangements with larger pharmaceutical and biotechnology companies. This strategic direction is evident from the company's recent transaction with XORTX, where the out-licensing of VB4-P5 was structured to provide continued exposure to development outcomes while removing internal funding obligations. The company's leadership appointments and engagement of regulatory expertise reflect preparation for interactions with potential strategic partners who may be interested in licensing or partnering arrangements for VB0004 or other pipeline assets.

The company's significantly reduced operating cost base creates flexibility for pursuing strategic transactions and partnerships. The appointment of Dr Speranza, with her extensive experience in capital markets, valuation, and transaction execution, reflects an organisational focus on identifying and executing strategic transactions. The engagement of Cardinal Health Regulatory Services positions the company to present VB0004 to potential partners with professional regulatory documentation and FDA engagement strategy already in place. This preparation may enhance the company's attractiveness to larger pharmaceutical companies seeking to in-license promising early-stage assets in the fibrotic disease space.

Orphan Drug Designation and IPF Market Opportunity

Vectus Biosystems is pursuing Orphan Drug Designation for VB0004 in idiopathic pulmonary fibrosis (IPF), as noted in the engagement of Cardinal Health Regulatory Services to prepare the Orphan Drug Designation Request. Orphan drug status in the United States provides substantial development and commercial incentives, including extended market exclusivity, tax credits for clinical trial costs, and exemptions from FDA user fees. IPF represents a recognised area of significant unmet medical need, with limited treatment options available despite the progressive and often fatal nature of the condition.

The fibrotic disease market represents a substantial therapeutic opportunity. IPF primarily affects the elderly population, with incidence increasing with age, and outcomes remain poor despite recent therapeutic advances. The company's antifibrotic approach—targeting the prevention and reversal of established fibrosis—represents a potentially differentiated mechanism compared to existing therapies. Securing Orphan Drug Designation would provide VB0004 with regulatory advantages that could facilitate clinical development and support future commercial positioning. The strategic focus on IPF as the initial indication reflects a prioritised approach to regulatory engagement and clinical trial planning.

Clinical-Stage Development Risks and Execution Challenges

Vectus Biosystems, as a clinical-stage biotechnology company, faces inherent risks associated with drug development, including the possibility that VB0004 may not demonstrate sufficient efficacy or safety in Phase Ib and subsequent clinical trials to support advancement to pivotal trials or regulatory approval. Preclinical demonstration of fibrosis reversal does not guarantee human clinical efficacy, and the transition from Phase Ia to Phase Ib testing introduces new uncertainties regarding dose escalation, safety profile expansion, and preliminary evidence of clinical benefit. Failure to demonstrate adequate safety or preliminary efficacy could require trial redesign, increased development costs, or discontinuation of the programme.

Additional execution risks include the company's limited cash resources relative to the capital intensity of clinical drug development. While the $791,000 placement provides near-term funding for VB0004 Phase Ib acceleration, the company will likely require additional capital raises to fund subsequent clinical phases and regulatory submissions. The timing and terms of future capital raises remain uncertain and could result in substantial dilution to existing shareholders. Regulatory interactions with the FDA, while supported by professional regulatory counsel, may result in requests for additional preclinical work or modified trial designs that could extend timelines and increase costs. Competitive developments in the fibrotic disease space, including clinical data from competitors' programmes, could impact the company's development strategy or commercial prospects for VB0004.

Next Milestones and Investor Monitoring Points

Investors in Vectus Biosystems should monitor several near-term and medium-term development milestones. In the immediate term, the company is expected to progress pre-IND communications with the FDA regarding VB0004 in IPF, with support from Cardinal Health Regulatory Services. The FDA's feedback on the company's development plan and the subsequent IND application filing represent critical regulatory milestones. Success in obtaining FDA clearance of the IND would permit the initiation of Phase Ib clinical trials, representing progression of VB0004 toward later-stage clinical evaluation.

Additionally, investors should monitor progress toward Orphan Drug Designation approval, which would provide substantial commercial and development incentives if granted. The advancement of VB0004 Phase Ib clinical trial activities—including patient recruitment, safety monitoring, and interim data generation—represents ongoing proof-of-concept evidence for the antifibrotic approach. Progress on potential licensing or partnership discussions with larger pharmaceutical companies could result in alternative development or funding pathways for VB0004. Updates regarding the value of the company's XORTX equity holding will provide information on the success of the VB4-P5 out-licensing transaction and the performance of that alternative investment. Further refinement of the company's development strategy for pipeline assets beyond VB0004 will provide visibility into the company's longer-term portfolio approach and value creation potential.